Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Bladder Cancer

  Free Subscription

Articles published in J Clin Oncol

Retrieve available abstracts of 13 articles:
HTML format

Single Articles

    August 2022
  1. ZHANG S
    Neoadjuvant Programmed Cell Death Protein 1 and Chemotherapy in Combination in Muscle-Invasive Urothelial Cancer: Promising, But Not Deserving to Try Further.
    J Clin Oncol. 2022;40:2656.
    PubMed     Abstract available

    July 2022
  2. GRIMM MO, Schmitz-Drager BJ, Zimmermann U, Grun CB, et al
    Tailored Immunotherapy Approach With Nivolumab in Advanced Transitional Cell Carcinoma.
    J Clin Oncol. 2022;40:2128-2137.
    PubMed     Abstract available

    June 2022
  3. ZENG S, Zhang Z, Xu C
    Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as the Gold Standard Neoadjuvant Chemotherapy Regimen for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer Remains Controversial.
    J Clin Oncol. 2022 Jun 15:JCO2200669. doi: 10.1200/JCO.22.00669.

    May 2022
  4. OWENS-WALTON J, Williams C, Rompre-Brodeur A, Pinto PA, et al
    Minority Enrollment in Phase II and III Clinical Trials in Urologic Oncology.
    J Clin Oncol. 2022;40:1583-1589.
    PubMed     Abstract available

    April 2022
  5. SONPAVDE GP, Mouw KW, Mossanen M
    Therapy for Muscle-Invasive Urothelial Carcinoma: Controversies and Dilemmas.
    J Clin Oncol. 2022;40:1275-1280.
    PubMed     Abstract available

    March 2022
  6. PFISTER C, Gravis G, Flechon A, Chevreau C, et al
    Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
    J Clin Oncol. 2022 Mar 7:JCO2102051. doi: 10.1200/JCO.21.02051.
    PubMed     Abstract available

    January 2022
  7. FUNT SA, Lattanzi M, Whiting K, Al-Ahmadie H, et al
    Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.
    J Clin Oncol. 2022 Jan 28:JCO2101485. doi: 10.1200/JCO.21.01485.
    PubMed     Abstract available

    October 2021
  8. POWLES T, Petrylak DP, Rosenberg JE
    Beyond Chemotherapy and Checkpoint Inhibitors: Weighing the Risks and Benefits of the Novel Therapies for Metastatic Urothelial Carcinoma.
    J Clin Oncol. 2021;39:3411-3412.

    August 2021
  9. ROSE TL, Harrison MR, Deal AM, Ramalingam S, et al
    Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.
    J Clin Oncol. 2021 Aug 24:JCO2101003. doi: 10.1200/JCO.21.01003.
    PubMed     Abstract available

  10. ROSENBERG JE, Ballman KA, Halabi S, Atherton PJ, et al
    Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).
    J Clin Oncol. 2021;39:2486-2496.
    PubMed     Abstract available

    December 2020
  11. CATTO JWF, Gordon K, Collinson M, Poad H, et al
    Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study.
    J Clin Oncol. 2020 Dec 17:JCO2001665. doi: 10.1200/JCO.20.01665.
    PubMed     Abstract available

    May 2020
  12. WINQUIST E, Booth CM
    Trimodality Therapy for Muscle-Invasive Bladder Cancer: Concurrent Chemotherapy is Not Enough.
    J Clin Oncol. 2020 May 27:JCO1902959. doi: 10.1200/JCO.19.02959.

    January 2020
  13. DE VERE WHITE R, Lara PN Jr, Black PC, Evans CP, et al
    Framing Pragmatic Strategies to Reduce Mortality From Bladder Cancer: An Endorsement From the Society of Urologic Oncology.
    J Clin Oncol. 2020 Jan 17:JCO1901731. doi: 10.1200/JCO.19.01731.

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.